Hims & Hers Health boosted at Citi on Novo Nordisk partnership - Seeking Alpha

Citi upgrades Hims & Hers to neutral after Novo Nordisk GLP-1 deal, raising price target to $24. Read more here.

You will be redirected in 10 seconds.